NCT03103724View on ClinicalTrials.gov

A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 16, 2017

Primary Completion Date

April 23, 2021

Study Completion Date

April 23, 2021

Conditions
Carcinoma Prostate
Interventions
DRUG

Xtandi

Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily

Trial Locations (1)

20133

Elena Verzoni, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT03103724 - A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease. | Biotech Hunter | Biotech Hunter